RG 7386Alternative Names: FAP-DR5 - Roche; RG7386; RO-6874813
Latest Information Update: 17 Feb 2016
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Cell death stimulants; TRAIL receptor 2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Sep 2015 Preclinical trials in Solid tumours in USA (IV)
- 25 Sep 2015 Roche plans a phase I trail for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA (NCT02558140)